Combination of immunotherapies for severe allergic asthma

Gülşen, Aşkın; Wallis, Sönke; Jappe, Uta

doi:10.1080/02770903.2019.1658204

Cited by 13 publications

(9 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 It has been recently reported that SIT can be combined with biological treatments, especially after asthma control has been achieved. 3 Although it appears easy to choose among the available biologics, some patients with severe asthma present overlapping features that may benefit from different treatments. Hence, in such situations, physicians have difficulty in prioritizing the optimal therapy for a given patient.…”

Section: Switching From Omalizumab To Mepolizumab: Real-life Experienmentioning

confidence: 99%

See 1 more Smart Citation

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Carpagnano

Pelaia

D’Amato

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic one, but not all respond to that selected as first choice. The aim of our real-life study was to assess whether, for patients with severe eosinophilic allergic asthma, not previously controlled by the anti-IgE omalizumab, the shift to another biologic targeting interleukin-5, such as mepolizumab, may represent a good therapeutic choice. Methods: A total of 41 consecutive patients with severe, persistent allergic, eosinophilic asthma, uncontrolled despite treatment with omalizumab, were enrolled in seven certified Clinical Respiratory Units of Southern Italy (Catania, Catanzaro, Foggia, Bari, Palermo, and two University Respiratory Units of Naples) and shifted to mepolizumab without a wash-out period. Data at baseline, after at least 12 months of therapy with omalizumab, and after at least 12 months of treatment with mepolizumab were collected. Results: After at least 12 months of therapy with mepolizumab, patients experienced a significant decrease in the number of exacerbations/year (5.8 ± 1.8 versus 0.7 ± 0.9, p < 0.0001), an increment of asthma control test score (12 ± 2.7 versus 21.9 ± 2.7, p < 0.0001), an increase in pre-bronchodilator forced expiratory volume in 1 s (1.56 ± 0.45 l versus 1.86 ± 0.52 l, p < 0.0001), and a reduction of blood eosinophils (584 ± 196 cells/µl versus 82 ± 56 cells/µl, p < 0.0001). The percentage of patients who were dependent on corticosteroids significantly decreased from 46% at baseline to 5% during treatment with mepolizumab. Conclusion: Results of our real-life multicentric experience confirms that the shift to mepolizumab could be a good therapeutic strategy in severe eosinophilic allergic asthma not previously controlled by omalizumab. The reviews of this paper are available via the supplemental material section.

show abstract

Section: Switching From Omalizumab To Mepolizumab: Real-life Experienmentioning

confidence: 99%

“…2 It has been recently reported that SIT can be combined with biological treatments, especially after asthma control has been achieved. 3…”

Section: Introductionmentioning

confidence: 99%

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Carpagnano

Pelaia

D’Amato

et al. 2020

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…Anyhow, as soon as an allergy could be proven to be the initiator of asthma, and the corresponding allergen could be identified, causative treatment strategies (like allergen-specific immunotherapy) can be introduced to the respective patients. Thereby a specific anti-inflammatory treatment can be provided and – if necessary – can be combined with treatment of disease-relevant target molecules (target treatments), like the application of biologicals against certain cytokines ( 45 ). In any case, the patients will profit considerably from an improved molecular allergy diagnostic test based on specifically recognized epitopes.…”

Section: Discussionmentioning

confidence: 99%

IgE Epitope Profiling for Allergy Diagnosis and Therapy – Parallel Analysis of a Multitude of Potential Linear Epitopes Using a High Throughput Screening Platform

et al. 2020

Self Cite

View full text Add to dashboard Cite

Krause et al. OBOC-Library Screening With IgE library by using IgE directed against those test-peptides at physiological concentrations (≤20 IU/ml of specific IgE), and disease-relevant bead-bound epitopes of the major peanut allergen Ara h 2 by screening with sera from peanut allergics. Thus, we established a platform with which one can find and validate new immunoglobulin targets using patient material which displays a largely unknown immunoglobulin repertoire.

show abstract

“…When asthma is controlled, the biologic treatment can be withdrawn because it has been demonstrated that the improvement in the efficacy and tolerability of subcutaneous AIT in children and adults with severe allergic asthma is maintained after biological treatment discontinuation [4,119,[122][123][124].…”

Section: Can the Biological Treatment (Omalizumab Or Others) Be Withdrawn In A Patient With Severe Asthma And Ait To Continue Only With Amentioning

confidence: 99%

Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview

Tabar

Delgado

González-Mancebo

et al. 2021

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The Global Initiative for Asthma Report updated in 2019 stated that potential benefits of allergen immunotherapy (AIT), compared to pharmacological and avoidance options, must be weighed against the risk of adverse effects and the inconvenience and cost of the prolonged course of therapy in asthma. Thus, with the aim of clarifying some aspects with regard to the possible use of AIT in allergic asthma treatment armamentarium, a group of expert allergists from the Spanish Allergy and Clinical Immunology Scientific Society (SEAIC), particularly from the Immunotherapy and Asthma Interest Groups developed a frequently asked questions in clinical practice. This document updates relevant topics on the use of AIT in asthma and could facilitate physician clinical decisions and improve health outcomes for individual patients.

show abstract

Combination of immunotherapies for severe allergic asthma

Cited by 13 publications

References 9 publications

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

IgE Epitope Profiling for Allergy Diagnosis and Therapy – Parallel Analysis of a Multitude of Potential Linear Epitopes Using a High Throughput Screening Platform

Recent Advances in Allergen-Specific Immunotherapy as Treatment for Allergic Asthma: A Practical Overview

Contact Info

Product

Resources

About